KRAS and colorectal carcinoma: Overall, we have not found a pronounced specificity of 9-ING-41 toward KRAS-mutated cells that poses a challenge of finding molecular biomarkers of 9-ING-41 efficacy in CRC, but we do demonstrate that 9-ING-41 inhibits the growth of colorectal cancer cells via a distinct from chemotherapy mechanism of action.